AccessMyLibrary provides FREE access to over 30 million articles from top publications available through your library.
Create a link to this page
Copy and paste this link tag into your Web page or blog:
ABRA Protein Fragments Halt P. falciparum Growth.(acidic basic repeat antigen of malaria is possible vaccine candidate)
2001 SEP 19 - (NewsRx.com & NewsRx.net) --
by N.R. Saltmarsh, staff medical writer - The acidic basic repeat antigen (ABRA) of Plasmodium falciparum stops 80%-90% of parasite growth and represents a promising vaccine candidate, researchers in India have found.
"The recombinant proteins representing different fragments of ABRA were expressed in Escherichia coli, either as fusions with maltose binding protein or as 6X histidine tagged molecules, and purified by affinity chromatography," reported A. Kushwaha and colleagues in New Delhi.
Animal studies using these constructs indicated that the N-terminal region is the least immunogenic part of ABRA and that the T-cell epitopes are localized in the middle portion of the protein.
More important, purified immunoglobulin G specific to middle and C-terminal fragments prevented parasite growth at levels approaching 80%-90%, and was recognized by sera from P. falciparum-infected patients from Rourkela, a malaria-endemic area of India, said Kushwaha and coworkers ("Immunogenicity of recombinant fragments of Plasmodium falciparum acidic basic repeat antigen produced in Escherichia coli," Parasite Immunology, August ...
- VaxInnate's Second Flu Vaccine Candidate Enters Clinical Development; Results...
- Press release article from: Business Wire September 30, 2008 700+ words
...announced that its second influenza vaccine candidate has entered clinical development...hemagglutinin (HA)-flagellin flu vaccine candidate. The study is taking place at the...are expected in early 2009. The HA vaccine candidate links the hemagglutinin (HA) antigen...
- GlaxoSmithKline's Rotavirus Vaccine Candidate Shown Effective Against Rotavirus...
- Press release article from: PR Newswire January 4, 2006 700+ words
...Establishes Safety Profile of New Rotavirus Vaccine Candidate PHILADELPHIA, Jan. 4 /PRNewswire...GlaxoSmithKline's (GSK) rotavirus vaccine candidate as effective against rotavirus disease...demonstrated that two doses of the rotavirus vaccine candidate given two months apart at two ...
- Merck's Investigational HIV/AIDS Vaccine Candidate Advances To Phase II...
- Press release article from: Business Wire January 24, 2005 700+ words
...Conduct First Efficacy Test of Merck Vaccine Candidate The HIV Vaccine Trials Network...global capacity of the HVTN. The vaccine candidate used in this study has generated...researchers to test the concept that the vaccine candidate prevents HIV infection, or results...
- Emergent BioSolutions Acquires Advanced Recombinant Protective Antigen Anthrax...
- Press release article from: Business Wire May 5, 2008 700+ words
...domestic source for an advanced anthrax vaccine candidate to meet planned procurement of 25...and Human Services (HHS). The vaccine candidate has completed one Phase 2 clinical...2008. The acquisition of this rPA vaccine candidate, and the pending RFP, have no effect...
- Emergent BioSolutions' Typhoid Vaccine Candidate Achieves Endpoints in Phase II...
- Press release article from: Business Wire October 10, 2007 700+ words
...single-dose, drinkable typhoid vaccine candidate achieved the study endpoints for...total of 101 children received the vaccine candidate and 50 children received placebo. The vaccine candidate and placebo were allocated in a...
- VaxInnate's Universal Flu Vaccine Candidate Shown Safe and Immunogenic in Phase...
- Press release article from: Business Wire October 26, 2008 700+ words
...production WASHINGTON -- A universal flu vaccine candidate that could end the need for annual...of VaxInnate's M2e universal flu vaccine candidate also validates the Cranbury, NJ...VaxInnate's M2e universal flu vaccine candidate has passed a critical initial test...
- Emergent BioSolutions Initiates U.S. Phase II Trial of Oral Typhoid Vaccine...
- Press release article from: Business Wire June 5, 2008 700+ words
...company's single-dose oral typhoid vaccine candidate. This randomized, double-blind...clinical development of our oral typhoid vaccine candidate," said Daniel Abdun-Nabi, president...previous clinical studies, this vaccine candidate has demonstrated promising immunogenicity...
- VaxInnate's M2e Universal Influenza Vaccine Candidate Demonstrates Safety and...
- Press release article from: Business Wire August 21, 2008 700+ words
...that its M2e universal influenza vaccine candidate was safe and immunogenic in its first...VaxInnate's M2e universal influenza vaccine candidate as very promising, based upon the...further studies of VaxInnate's vaccine candidate, which has the potential to be a...
- Merck's Investigational HIV Vaccine Candidate to be Studied In Collaborative...
- Press release article from: Business Wire September 19, 2003 700+ words
...clinical trial of Merck's HIV vaccine candidate in 18 cities around the...the first study of an HIV vaccine candidate to take place in so many...their investigational HIV vaccine candidate on a truly global scale...
- VaxInnate's second flu vaccine candidate enters clinical development; results...
- News wire article from: Chemical Business Newsbase September 30, 2008 700+ words
...announced that its second influenza vaccine candidate has entered clinical development...haemagglutinin (HA)-flagellin flu vaccine candidate. The study is taking place at the...are expected in early 2009. The HA vaccine candidate links the haemagglutinin (HA) antigen...
Source: HighBeam Research, ABRA Protein Fragments Halt P. falciparum Growth.(acidic basic repeat...